Prospective Case-Control Study of Cardiovascular Changes in Pregnancy Related Hypertensive Disorders (ARTSEN)
Pre-Eclampsia
About this trial
This is an interventional diagnostic trial for Pre-Eclampsia
Eligibility Criteria
Case Inclusion Criteria:
- Adult females age > 18 years
- Must be able to read and understand English and consent for themselves
- Must have a singleton pregnancy and a diagnosis of preeclampsia or gestational hypertension
- Must be willing and able to come to West Penn Hospital for post-partum visits at 6-8 weeks and then at 6-7 months.
Case Exclusion Criteria:
- Prior history of hypertension
- Multiple pregnancies
- Other comorbidities such as congenital heart disease, dialysis dependent renal failure, heroin abuse, cocaine abuse, pulmonary hypertension, congestive heart failure, autoimmune conditions such as SLE or severe lung disease.
- Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Control Inclusion Criteria:
- Adult females age > 18 years
- Must be able to read and understand English and consent for themselves
- Must have a singleton pregnancy and not have a prior or current diagnosis of hypertension
- Must be willing and able to come to West Penn Hospital for post-partum visits at 6-8 weeks.
Control Exclusion Criteria:
- Prior history and/or current diagnosis of hypertension
- Multiple pregnancies
- Other comorbidities such as congenital heart disease, dialysis dependent renal failure, heroin abuse, cocaine abuse, pulmonary hypertension, congestive heart failure, autoimmune conditions such as SLE or severe lung disease.
- Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
Sites / Locations
- West Penn HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Active Comparator
Pregnant with Pre-eclampsia
Pregnant with gestational hypertension
Pregnant without Hypertension - Control
There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit will be 6-7 months post partum where there is a collection of a clinical questionnaire, demographics, vitals, chart review, echocardiogram and vascular compliance will be re-measured.
There will be an initial 'Pregnancy' visit within 7-10 days of the screening visit, when the subject will undergo an echocardiogram, have the vascular compliance measurements and will have blood drawn for measurement of serum biomarkers. The second study visit will be the '6-8 weeks post-partum' visit when the echocardiogram and vascular compliance will be re-measured, along with assessment of vitals and medication history. The third study visit is not applicable to the control group.